Q2 2025 Holdings
Filed 2025-08-11 | 89 holdings | $220.6M | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↑ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Mereo BioPharm Group PLC(MREO) | Common | 589492107 | $865.4K | 319,337 | 0.4% |
| AbbVie Inc.(ABBV) | Common | 00287Y109 | $935.0K | 5,037 | 0.4% |
| Myriad Genetics, Inc.(MYGN) | Common | 62855J104 | $955.8K | 180,000 | 0.4% |
| Johnson & Johnson(JNJ) | Common | 478160104 | $1.1M | 6,922 | 0.5% |
| Liquidia Corporation(LQDA) | Common | 53635D202 | $1.1M | 90,000 | 0.5% |
| Ryman Hospitality Properties, Inc.(RHP) | Common | 78377T107 | $1.2M | 12,000 | 0.5% |
| Bristol-Myers Squibb Company(BMY) | Common | 110122108 | $1.2M | 27,000 | 0.6% |
| The Panagram Bbb-B CLO ETF(CLOZ) | Common | 81752T528 | $1.3M | 47,807 | 0.6% |
| Viridian Therapeutics, Inc.(VRDN) | Common | 92790C104 | $1.3M | 91,483 | 0.6% |
| Alkermes PLC(ALKS) | Common | G01767105 | $1.4M | 49,000 | 0.6% |
| Tectonic Therapeutic, Inc.(TECX) | Common | 878972108 | $1.5M | 74,000 | 0.7% |
| AtriCure, Inc.(ATRC) | Common | 04963C209 | $1.5M | 46,443 | 0.7% |
| Arcellx Inc(ACLX) | Common | 03940C100 | $1.7M | 25,700 | 0.8% |
| Pfizer Inc.(PFE) | Common | 717081103 | $1.8M | 74,537 | 0.8% |
| Ultragenyx Pharmaceutical Inc.(RARE) | Common | 90400D108 | $1.9M | 52,000 | 0.9% |
| AllianceBernstein Holding L.P.(AB) | Common | 01881G106 | $2.0M | 48,000 | 0.9% |
| CSX Corporation(CSX) | Common | 126408103 | $2.3M | 70,000 | 1.0% |
| Lenz Therapeutics, Inc.(LENZ) | Common | 52635N103 | $2.4M | 82,000 | 1.1% |
| Enstar Group Limited | Common | G3075P101 | $2.5M | 7,500 | 1.1% |
| Inozyme Pharma, Inc. | Common | 45790W108 | $2.7M | 666,204 | 1.2% |
| BioCryst Pharmaceuticals, Inc.(BCRX) | Common | 09058V103 | $3.0M | 332,625 | 1.4% |
| Syndax Pharmaceutical, Inc.(SNDX) | Common | 87164F105 | $3.3M | 352,778 | 1.5% |
| Bridgebio Pharma, Inc.(BBIO) | Common | 10806X102 | $3.5M | 80,000 | 1.6% |
| Avadel Pharmaceuticals plc | Common | G29687103 | $3.8M | 426,000 | 1.7% |
| Catalyst Pharmaceuticals, Inc.(CPRX) | Common | 14888U101 | $3.8M | 176,000 | 1.7% |
| Travere Therapeutics, Inc.(TVTX) | Common | 89422G107 | $3.8M | 260,000 | 1.7% |
| Protagonist Therapeutics, Inc(PTGX) | Common | 74366E102 | $4.4M | 80,000 | 2.0% |
| DocGo, Inc.(DCGO) | Common | 256086109 | $4.8M | 3,070,850 | 2.2% |
| Xeris Biopharma Holdings, Inc.(XERS) | Common | 98422E103 | $5.0M | 1,060,000 | 2.2% |
| Verona Pharma Plc.(VRNA) | Common | 925050106 | $5.2M | 55,000 | 2.4% |
| JPMorgan Chase & Co.(JPM) | Common | 46625H100 | $6.1M | 20,985 | 2.8% |
| Alphabet Inc(GOOG) | Common | 02079K107 | $19.9M | 112,220 | 9.0% |
| Janus Henderson AAA CLO ETF(JAAA) | Common | 47103U845 | $25.1M | 495,254 | 11.4% |
| Apollo Global Management, Inc.(APO) | Common | 03769M106 | $31.9M | 225,000 | 14.5% |
| Calumet, Inc.(CLMT) | Common | 131428104 | $51.6M | 3,275,231 | 23.4% |